1945 Company predecessor, Glucose Corporation, instilled.
Oct. 1962 Company reorganized as Sintong Chemical Industry Company, Limited with $35 million paid-in capitalization as an integrated local pharmaceutical producer.
1979 20ml BFS filler machine procured marking the firm as a premiere local SVP?] small volume parenteral?^producer.
1987 * Paid-in capitalization upped to $200 million with IPO completed and passed GMP?]Good Manufacture Practice?^inspection.
* Representation of Japan's Nikkiso hemodialysis equipment as the agency embarked on the medical treatment equipment and related field.
* Exports reaching Vietnam to excel Sintong in global expansion.
* Full computerization inducted.
1988 Launched the first bio-equivalent test product in Taiwan, Ranidine, formally certified by the Department of Health.
1989 * Addition of 20ml BFS filling machine.
* Investment in Taiwan Biotech Co., Ltd offering upstream Active Pharmaceutical Ingredients (APIs).
1990 * Technical pact with the Japanese Eisai in jointly producing Aminol-K and the presentation of many of its related products.
* Joint development of transdermal delivery drug system (TDDS) with an U.S.A. Pharmaceutical Development company.
1992 * Accredited with Outstanding Award in the first Outstanding Biotech Awards by the Ministry of Economic Affairs.
* Bestowed with a pilot new product R&D plan for transdermal products sanctioned by the Ministry of Economic Affairs' Bureau of Industrial Development.
1993 * Accredited with an Outstanding Award by the ROC Biotech Industry Development Council.
* Branch office launched at the Hsinchu Science-based Industrial Park.
1994 * Curie Chemicals and Pharmaceuticals Manufacturing Co., Ltd's plant joined Taiwan Biotech's production line in producing oral products.
* The addition of 10ml BFS filler machine.
* API plant certified by the U.S. Food & Drug Administration.
1995 Innovative transdermal nicotine patch, Smokfree, debuted.
1996 AnPo, a labour inhibitors, debuted.
1997 Export of a 20ml BFS?]Bill-Flow-Seal?^to Japan began
1998 * Reinvestments made at Huaneng Pharmaceutical Company in Mainland China.
* Dynamics Venture Capital formed in a move to integrate the company's venture investments.
1999 * Represent the U.S. pharmaceutical company, Ocular Sciences' contact lenses.
* Sales and marketing of respiratory system medical equipment, began.
* Investments made to the U.S. company, Optics Corporation, through which TBC's products started to export to the U.S.
2001 * Renamed as Taiwan Biotech Company, Limited.-
* Represent the U.S. pharmaceutical company, Cephalon's Provigil- a narcolepsy treatment solution.-
* Implemented and surpassed the cGMP phase-one review.
2002 * Biotech food manufactory launched at the Hsinchu Science-based Industrial Park.
* Strategic alliance formed with Fresenius Medical Care Corporation of Germany.
2003 Implemented and surpassed the cGMP(II)-process validation review.
2004 * Accredited with pharmaceutical technology research award in the third pharmaceutical technology research awards by the department of health executive yuan.
* Accredited with orphan drug research award in the third orphan drug research awards by the department of health executive yuan.
2005 * Implemented and surpassed the cGMP(III)-computer validation review.
* Accredited with pharmaceutical technology research award in the forth pharmaceutical technology research awards by department of health executive yuan.
* Eye-Cept Rewetting Drops got FDA?|s approval of 510(k) for contact lens care products in USA.
* Purchasing the Kuan Yin plant of Fujisawa Pharmaceutical Co., Ltd in Taiwan.
* Acquired management authority of The Veterans Pharmaceutical Plant.
Oct. 1962 Company reorganized as Sintong Chemical Industry Company, Limited with $35 million paid-in capitalization as an integrated local pharmaceutical producer.
1979 20ml BFS filler machine procured marking the firm as a premiere local SVP?] small volume parenteral?^producer.
1987 * Paid-in capitalization upped to $200 million with IPO completed and passed GMP?]Good Manufacture Practice?^inspection.
* Representation of Japan's Nikkiso hemodialysis equipment as the agency embarked on the medical treatment equipment and related field.
* Exports reaching Vietnam to excel Sintong in global expansion.
* Full computerization inducted.
1988 Launched the first bio-equivalent test product in Taiwan, Ranidine, formally certified by the Department of Health.
1989 * Addition of 20ml BFS filling machine.
* Investment in Taiwan Biotech Co., Ltd offering upstream Active Pharmaceutical Ingredients (APIs).
1990 * Technical pact with the Japanese Eisai in jointly producing Aminol-K and the presentation of many of its related products.
* Joint development of transdermal delivery drug system (TDDS) with an U.S.A. Pharmaceutical Development company.
1992 * Accredited with Outstanding Award in the first Outstanding Biotech Awards by the Ministry of Economic Affairs.
* Bestowed with a pilot new product R&D plan for transdermal products sanctioned by the Ministry of Economic Affairs' Bureau of Industrial Development.
1993 * Accredited with an Outstanding Award by the ROC Biotech Industry Development Council.
* Branch office launched at the Hsinchu Science-based Industrial Park.
1994 * Curie Chemicals and Pharmaceuticals Manufacturing Co., Ltd's plant joined Taiwan Biotech's production line in producing oral products.
* The addition of 10ml BFS filler machine.
* API plant certified by the U.S. Food & Drug Administration.
1995 Innovative transdermal nicotine patch, Smokfree, debuted.
1996 AnPo, a labour inhibitors, debuted.
1997 Export of a 20ml BFS?]Bill-Flow-Seal?^to Japan began
1998 * Reinvestments made at Huaneng Pharmaceutical Company in Mainland China.
* Dynamics Venture Capital formed in a move to integrate the company's venture investments.
1999 * Represent the U.S. pharmaceutical company, Ocular Sciences' contact lenses.
* Sales and marketing of respiratory system medical equipment, began.
* Investments made to the U.S. company, Optics Corporation, through which TBC's products started to export to the U.S.
2001 * Renamed as Taiwan Biotech Company, Limited.-
* Represent the U.S. pharmaceutical company, Cephalon's Provigil- a narcolepsy treatment solution.-
* Implemented and surpassed the cGMP phase-one review.
2002 * Biotech food manufactory launched at the Hsinchu Science-based Industrial Park.
* Strategic alliance formed with Fresenius Medical Care Corporation of Germany.
2003 Implemented and surpassed the cGMP(II)-process validation review.
2004 * Accredited with pharmaceutical technology research award in the third pharmaceutical technology research awards by the department of health executive yuan.
* Accredited with orphan drug research award in the third orphan drug research awards by the department of health executive yuan.
2005 * Implemented and surpassed the cGMP(III)-computer validation review.
* Accredited with pharmaceutical technology research award in the forth pharmaceutical technology research awards by department of health executive yuan.
* Eye-Cept Rewetting Drops got FDA?|s approval of 510(k) for contact lens care products in USA.
* Purchasing the Kuan Yin plant of Fujisawa Pharmaceutical Co., Ltd in Taiwan.
* Acquired management authority of The Veterans Pharmaceutical Plant.
